Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Erythromycin and common cold in COPD.

T Suzuki1, M Yanai, M Yamaya

  • 1Department of Geriatric and Respiratory Medicine, Tohoku University School of Medicine, Sendai, Japan.

Chest
|September 14, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Insulin antibody does not cause insulin resistance during glucose clamping in rats.

Diabetes research and clinical practice·1992
Same author

Parental methylation patterns of a transgenic locus in adult somatic tissues are imprinted during gametogenesis.

Development (Cambridge, England)·1992
Same author

Extracellular matrix formation in piecemeal necrosis: immunoelectron microscopic study.

Liver·1992
Same author

Daily energy expenditure in active and inactive persons with spinal cord injury.

Journal of human ergology·1992
Same author

Perivascular fibrosis of muscular pulmonary arteries in chronic obstructive pulmonary disease.

Chest·1992
Same author

Partitioning of pulmonary responses to inhaled methacholine in subjects with asymptomatic asthma.

The American review of respiratory disease·1992
Same journal

The effect of a two-day stay at high altitude (2500 m) on right ventricular afterload and oxygen delivery in patients with pulmonary vascular disease A randomized controlled crossover trial.

Chest·2026
Same journal

A Comparative Study of Radiation Exposure in Conventional and Robotic Bronchoscopy.

Chest·2026
Same journal

Independent Prognostic Contributions of Anti-Ro52 and Anti-MDA5 in Autoimmune-Associated Interstitial Lung Disease.

Chest·2026
Same journal

Lung aeration and gas exchange in SGA or AGA infants with moderate-severe BPD: secondary analysis of the PATH-BPD study.

Chest·2026
Same journal

Lung Cancer Incidence and Mortality after Negative Low-Dose CT Screening Results.

Chest·2026
Same journal

Symptom prevalence and impact on lung cancer risk in the SUMMIT study.

Chest·2026
See all related articles

Erythromycin therapy significantly reduced common colds and COPD exacerbations in patients. This macrolide antibiotic treatment offers a promising preventative strategy for respiratory infections in COPD management.

Area of Science:

  • Respiratory Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease.
  • Frequent respiratory infections, including the common cold, can trigger COPD exacerbations.
  • Effective preventative strategies for infections in COPD patients are crucial for disease management.

Purpose of the Study:

  • To evaluate the efficacy of erythromycin therapy in reducing the incidence of the common cold.
  • To determine if erythromycin therapy decreases the frequency of COPD exacerbations.
  • To assess the impact of erythromycin on COPD-related hospitalizations.

Main Methods:

  • Prospective, randomized, controlled trial involving 109 COPD patients.
  • Patients were assigned to either erythromycin therapy or a control group (no active treatment).

Related Experiment Videos

  • Observations were conducted over 12 months, monitoring common colds and COPD exacerbations.

    • Main Results:

    • Erythromycin group experienced significantly fewer common colds (1.24 vs 4.54 per person) and exacerbations (11% vs 56%).
    • The relative risk of multiple colds was 9.26 times higher, and exacerbations 4.71 times higher in the control group.
    • Fewer hospitalizations due to exacerbations were observed in the erythromycin group.

    Conclusions:

    • Erythromycin therapy demonstrates significant benefits in preventing exacerbations in COPD patients.
    • The macrolide antibiotic effectively reduces the frequency of common colds, a known trigger for COPD exacerbations.
    • Erythromycin represents a potential therapeutic option for managing respiratory infections and improving outcomes in COPD.